GLP-1R/GIPR dual agonists, such as tirzepatide, are a new class of drugs of great interest, because they have been shown to obtain greatly significant reductions in body weight in both T2DM and obese patients [154]. Here, GLP1R is linked to type 2 diabetes mellitus.